Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Public ClinicalTrials.gov record NCT02878603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Study identification
- NCT ID
- NCT02878603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- Caplacizumab Biological
- Standard of Care Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2016
- Primary completion
- Oct 22, 2020
- Completion
- Oct 22, 2020
- Last update posted
- Mar 27, 2022
2016 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator site | St Louis | Missouri | 63110 | — |
| Investigator site | Valhalla | New York | 10595 | — |
| Investigator Site | Durham | North Carolina | 27710 | — |
| Investigator Site | Columbus | Ohio | 43210 | — |
| Investigator Site | Oklahoma City | Oklahoma | 73104 | — |
| Investigator site | Pittsburgh | Pennsylvania | 15232 | — |
| Investigator Site | Charleston | South Carolina | 29425 | — |
| Investigator site | Greenville | South Carolina | 27834 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02878603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02878603 live on ClinicalTrials.gov.